The Potential Impact of Watson for Clinical Oncology – Part 3

Chapter 3

In this video, Andrew Norden, MD, MPH, MBA, deputy chief health officer at IBM Watson Health in Boston, Massachusetts, discusses how IBM’s Watson program is expected to help recommend treatments for patients with cancer.

Chapter 1

The Potential Impact of Watson for Clinical Oncology – Part 1

In this video, Andrew Norden, MD, MPH, MBA, deputy chief health officer at IBM Watson Health in Boston, Massachusetts, discusses how IBM’s Watson program is expected to help recommend treatments for patients with cancer.

Chapter 2

The Potential Impact of Watson for Clinical Oncology – Part 2

In this video, Andrew Norden, MD, MPH, MBA, deputy chief health officer at IBM Watson Health in Boston, Massachusetts, discusses how IBM’s Watson program is expected to help recommend treatments for patients with cancer.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs